A patient with maculopapular rash and lichenoid skin damage caused by ponatinib

Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicia...

Descripción completa

Detalles Bibliográficos
Autores principales: Teigen, Ingrid Anna, Sæle, Anna Kristine Myrmel, Reikvam, Håkon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/
https://www.ncbi.nlm.nih.gov/pubmed/32242465
http://dx.doi.org/10.1177/0300060520903660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/
https://www.ncbi.nlm.nih.gov/pubmed/32242465
http://dx.doi.org/10.1177/0300060520903660

Ejemplares similares